Illumina, Inc. (NASDAQ: ILMN) today announced that reimbursement has been granted for its FDA-approved in vitro diagnostic ...
BOSTON, May 30, 2025 /PRNewswire/ -- Velsera announces that its clinical Knowledgebase is powering the interpretation framework behind Illumina's TruSight™ Oncology Comprehensive (TSO Comp) assay, ...
Illumina, Inc. ILMN launched the TruSight Oncology (“TSO”) Comprehensive (EU)— a single test that evaluates multiple tumor genes and biomarkers to identify the specific molecular profile of a ...
Illumina secures CMS reimbursement for TruSight Oncology Comprehensive, expanding access to precision oncology: San Diego Thursday, January 22, 2026, 17:00 Hrs [IST] Illumina, Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results